

## Contents

VOLUME 10 ISSUE 1 FEBRUARY

- 1 Review article: the medical management of Crohn's disease. E. ELTON & S. B. HANAUER
- 23 Review article: Drug-induced pancreatitis. K. E. McARTHUR
- 39 Review article: refractory distal colitis—explanations and options. M. G. GRIFFIN & P. B. MINER
- 49 Conference report: duodenal ulcer trial reports at the European *Helicobacter pylori* Study Group, Edinburgh 1995. G. D. BELL
- 55 Clinical Economics Review: gastroenterology. K. BODGER, M. J. DALY, R. V. HEATLEY & D. R. R. WILLIAMS
- 61 A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. B. TERMANINI, F. GIBRIL, C. A. STEWART, H. C. WEBER & R. T. JENSEN
- 73 Ropivacaine gel in active distal ulcerative colitis and proctitis—a pharmacokinetic and exploratory clinical study. E. ARLANDER, Å. ÖST, D. STÅHLBERG & R. LÖFBERG
- 83 A survey of dyspepsia in Great Britain. J. G. PENSTON & R. E. POUNDER
- 91 Symptomatology, quality of life and economic features of irritable bowel syndrome—the effect of hypnotherapy. L. A. HOUGHTON, D. J. HEYMAN & P. J. WHORWELL
- 97 Prevention of water immersion stress-induced gastric lesions through the enhancement of nitric oxide synthase activity in rats. K. TACHI, H. GOTO, T. HAYAKAWA & S. SUGIYAMA
- 105 The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. A. F. GODDARD & R. C. SPILLER
- 111 The effects of omeprazole and famotidine on mucin and PGE release in the rat stomach. K. YOSHIMURA, S. G. DELBARRE, E. KRAUS & C. R. BOLAND
- 119 Metronidazole, ranitidine and clarithromycin combination for treatment of *Helicobacter pylori* infection (modified Bazzoli's triple therapy). M. M. YOUSFI, H. M. T. EL-ZIMAITY, R. A. COLE, R. M. GENTAL & D. Y. GRAHAM

## VOLUME 10 ISSUE 2 APRIL

- 123 Review article: quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy. M. J. WELDON, C. LOWE, A. E. A. JOSEPH & J. D. MAXWELL
- 133 Gastric mucosal injury and adaptation to oral and rectal administration of naproxen. G. R. LIPSCOMB & W. D. W. REES
- 139 Eradication of *Helicobacter pylori* in general practice. J. G. PENSTON & K. R. MISTRY
- 147 Repeat prescribing of ulcer healing drugs in general practice—prevalence and underlying diagnosis. B. M. GOUDIE, P. E. MCKENZIE, J. CIPRIANO, E. M. GRIFFIN & F. E. MURRAY
- 151 Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. L. AABAKKEN & W. W. FRENZEL
- 157 Sulphasalazine treatment and the colorectal mucosa-associated flora in ulcerative colitis. M. G. HARTLEY, M. J. HUDSON, E. T. SWARBRICK, R. H. GRACE, A. E. GENT & M. D. HELLIER
- 165 Treatment of *Helicobacter pylori* infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. R. W. M. VAN DER HULST, J. F. L. WEEL, S. B. VERHEUL, J. J. KELLER, F. J. W. TEN KATE, A. VAN DER ENDE, E. A. J. RAUWS, J. DANKERT & G. N. J. TYTGAT
- 173 Mast cells do not contribute to nonsteroidal anti-inflammatory drug-induced gastric mucosal injury in rodents. K. P. RIOUX & J. L. WALLACE
- 181 Gastric mucosal infiltration by *Helicobacter pylori* favours bacterial survival after treatment. M. NERI, D. SUSI, I. BOVANI, F. LATERZA, E. PORRECA, F. CUCCURULLO
- 187 24-hour intragastric acidity following early evening or bedtime administration of roxatidine in patients with duodenal ulcer. M. LAZZARONI, O. SANGALETTI, S. BARGIGGIA, G. BENSI, A. CANALI & G. BIANCHI PORRO
- 193 Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulcer and eradicating *Helicobacter pylori* infection. T. STUPNICKI, M. TAUFER, H. DENK, M. RATSCHKE, P. SPATH & GRAF
- 199 Viral nucleotide changes in asymptomatic hepatitis B carriers undergoing treatment. W. HOW, W. C. NG, M. F. TAN, B. L. SEET & R. GUAN
- 203 High effectiveness and safety of one-week antibiotic regimen in *Helicobacter pylori* eradication. M. DALLA LIBERA, P. PAZZI, G. CARLI, S. GAMBERINI, R. SCAGLIARINI, A. MERIGHI & S. GULLINI
- 207 One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of *Helicobacter pylori* infection. J. LABENZ, M. STOLTE, U. PEITZ, B. TILLENBURG, T. BECKER & G. BÖRSCH
- 211 Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of *H. pylori* infection in duodenal ulcer patients. F. PARENTE, G. MACONI, S. BARGIGGIA, E. COLOMBO & G. BIANCHI PORRO
- 215 Letter to the Editors. R. A. GOODLAD

## VOLUME 10 ISSUE 3 JUNE

- 217 Letter from the Editors. R. E. POUNDER & W. L. PETERSON
- 219 Review article: renal circulatory changes in cirrhosis—pathogenesis and therapeutic prospects. E. H. FORREST, R. JALAN & P. C. HAYES
- 233 Clinical economics review: gastrointestinal disease in primary care. R. H. JONES
- 241 Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate–ranitidine admixture. A. A. McCOLM, A. McLAREN, G. KLINKERT, M. R. FRANCIS, P. C. CONNOLLY, C. J. GRINHAM, C. J. CAMPBELL, S. SELWAY & R. WILLIAMSON
- 251 Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating *H. pylori* and reducing ulcer recurrence. W. L. PETERSON, A. A. CIOCIOLA, D. L. SYKES, D. J. MCSORLEY, D. D. WEBB & THE RBC *H. PYLORI* STUDY GROUP
- 263 Omeprazole–amoxycillin versus omeprazole–amoxycillin–clarithromycin in the eradication of *Helicobacter pylori*. J. C. DELCHIER, I. ELAMINE, D. GOLDFAIN, S. CHAUSSADE, P. BARTHELEMY & J. P. IDSTRÖM
- 269 Prospective evaluation of the macrolide antibiotic dirithromycin for the treatment of *Helicobacter pylori*. L. LAINE, C. STEIN, F. GARCIA, M. TRUJILLO & R. ESTRADA
- 275 Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of *H. pylori* infection. B. H. JAUP & A. NORRBY
- 279 A seven-day *Helicobacter pylori* treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. M. J. WELDON, A. BROADBENT, S. CHAMBERS, R. MISTRY, L. RANGANATH & S. R. GOULD
- 285 Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for *Helicobacter pylori* infection. A. TURSI, G. CAMMAROTA, M. MONTALTO, A. PAPA, G. VENETO, L. CUOCO, F. TRUA, G. FEDELI & G. GASBARRINI
- 289 Effect of proton pump inhibitors on the detection of *Helicobacter pylori* in gastric biopsies. W. DICKEY, B. D. KENNY & J. B. McCONNELL
- 295 Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in *Helicobacter pylori*-positive healthy subjects. W. POMMERIEN, M. BRAUN, J.-P. IDSTRÖM, M. WRANGSTADH & W. LONDONG
- 303 Dose–response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of *Helicobacter pylori*. W. POMMERIEN, V. SCHULTZE, B. BRADEN, B. LEMBCKE, M. WRANGSTADH & W. LONDONG
- 309 Methotrexate for the treatment of refractory Crohn's disease. M. LÉMANN, C. CHAMOT-PRIEUR, B. MESNARD, M. HALPHEN, B. MESSING, J.-C. RAMBAUD, J.-P. GENDRE, J.-F. COLOMBEL & R. MODIGLIANI
- 315 Picotamide inhibition of excess *in vitro* thromboxane B<sub>2</sub> release by colorectal mucosa in inflammatory bowel disease. C. E. COLLINS, M. J. BENSON, W. R. BURNHAM & D. S. RAMPTON
- 321 Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. S. ACCIUFFI, S. GHOSH & A. FERGUSON
- 327 Distribution of mesalazine enemas in active and quiescent ulcerative colitis. A. A. VAN BODEGRAVEN, R. O. BOER, J. LOURENS, H. A. R. E. TUYNMAN, J. W. SINDRAM
- 333 How accurate is the determination of blood in gastric juice? Comparison of peroxidase and porphyrin methods. K. L. WOODS, C. KEIFE & D. Y. GRAHAM

Continued overleaf

- 339 The role of acid in the pathogenesis of indomethacin-induced gastric antral ulceration in the rat. N. M. CLAYTON, I. OAKLEY, L. V. WILLIAMS & M. A. TREVETHICK
- 347 High-dose ranitidine for the prevention of recurrent peptic disease in rheumatoid gastritis patients taking NSAIDs. S. TEN WOLDE, B. A. C. DIJMANS, M. JANSSEN, J. HERMANS & C. B. H. W. LAMERS
- 353 Diagnostic interpretation of the 24-hour intragastric pH-metry using a pattern recognition method. B. HUNYADY, I. JURICKSKAY, F. PAKODI, Cs. HORVÁTH & Gy. MÓZSIK
- 359 Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. M. HARTMANN, U. THEIß, R. HUBER, R. LÜHMANN, H. BLIESATH, W. WURST & P. W. LÜCKER
- 367 The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients. V. SAVARINO, G. S. MELA, P. ZENTILIN, M. R. MELE, S. VIGNERI, C. MANSI & G. CELLE
- 373 Ranitidine 300 mg twice daily and 150 mg four-times daily are effective in healing erosive oesophagitis. M. T. SILVER, R. H. MURDOCK JR, B. B. MORRILL & S. O. SUE
- 381 A trial of lansoprazole in refractory gastric ulcer. C. J. RENSBERG, J. A. LOUW, A. H. GIRDWOOD, A. E. SIMJEE & I. N. MARKS
- 387 The management of refractory gastric ulcer using  $H_2$ -receptor antagonists. G. S. RAJU, K. D. BARDHAN, C. ROYSTON & J. BERESFORD
- 397 Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. C. J. VAN RENSBERG, P. J. HONIBALL, H. DE K. GRUNDLING, J. H. VAN ZYL, S. K. SPIES, F. P. ELOFF, A. E. SIMJEE, I. SEGAL, J. F. BOTHA, A. K. CARIEM, I. N. MARKS, I. THERON & T. D. BETHKE
- 403 Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility. M. CAMILLERI, R. K. BALM & A. R. ZINSMEISTER
- 411 Effect of deloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity *in vivo*. C. SCARPIGNATO, I. KISFALVI, M. D'AMATO & G. VARGA
- 421 Effect of erythromycin on human biliary motility. T. WEHRMANN, C. PFELTZER & W. F. CASPARY
- 427 Gastric emptying of pancreatin granules and dietary lipids in pancreatic insufficiency. P. NØRREGAARD, J. LYSGAARD MADSEN, S. LARSEN, H. WØRNING
- 433 Pancreatin preparations used in the treatment of cystic fibrosis—lipase content and *in vitro* release. M. P. WALTERS & J. M. LITTLEWOOD
- 441 Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease (GERD). B. SIMON, G.-P. RAVELLI & H. GOFFIN
- 447 Letters to the Editors. V. SAVARINO, G. S. MELA & S. VIGNERI and J. HENDEL, L. HENDEL & S. AGGESTRUP

## VOLUME 10 ISSUE 4 AUGUST

- 449 Review article: the management of pouchitis.  
M. R. B. KEIGHLEY
- 459 Review article: safety of bismuth in the  
treatment of gastrointestinal diseases.  
L. A. TILLMAN, F. M. DRAKE, J. S. DIXON &  
J. R. WOOD
- 469 Review article: clinical aspects of *Helicobacter*  
*pylori* eradication therapy in peptic ulcer  
disease. J. G. PENSTON
- 487 Review article: older systemic and newer  
topical glucocorticosteroids and the  
gastrointestinal tract. A. THIESEN &  
A. B. R. THOMSON
- 497 Long-term treatment with lansoprazole of  
patients with duodenal ulcer and basal acid  
output of more than 15 mmol/h.  
B. I. HIRSCHOWITZ, J. MOHNEN & S. SHAW
- 507 Long-term treatment with lansoprazole for  
patients with Zollinger–Ellison syndrome.  
B. I. HIRSCHOWITZ, J. MOHNEN & S. SHAW
- 523 Morning versus evening dosing of lansoprazole  
30 mg daily on twenty-four-hour intragastric  
acidity in healthy subjects. A. G. FRASER,  
A. M. SAWYERR, M. HUDSON,  
M. S. H. SMITH & R. E. POUNDER
- 529 Lansoprazole versus ranitidine in the  
maintenance treatment of reflux oesophagitis.  
A. L. GOUGH, R. G. LONG, B. T. COOPER,  
C. S. FOSTER, A. D. GARRETT &  
C. H. LANGWORTHY
- 541 Effect of short- and long-term treatment with  
omeprazole on the absorption and serum levels  
of cobalamin. B. E. SCHENK,  
H. P. M. FESTEN, E. J. KUIPERS,  
E. C. KLINKENBERG-KNOL &  
S. G. M. MEUWISSEN
- 547 Reflux symptom relief with omeprazole in  
patients without unequivocal oesophagitis.  
C. M. BATE, S. M. GRIFFIN,  
P. W. N. KEELING, A. T. R. AXON,  
M. W. DRONFIELD, R. W. G. CHAPMAN,  
D. O'DONOGHUE, J. CALAM, J. CROWE,  
R. A. MOUNTFORD, D. A. WATTS,  
M. D. TAYLOR & P. D. I. RICHARDSON
- 557 Altered bowel function and duodenal bacterial  
overgrowth in patients treated with omeprazole.  
S. J. LEWIS, S. FRANCO, G. YOUNG &  
S. J. D. O'KEEFE
- 563 Effects of misoprostol on healing and prevention  
of biopsy-induced gastroduodenal lesions  
occurring during the administration of  
diclofenac to volunteers. G. DORTA,  
M. NICOLET, D. VOUILLAMOZ,  
D. MARGALITH, A. L. BLUM &  
D. ARMSTRONG
- 571 Omeprazole prevents indomethacin-induced  
gastric ulcers in rabbits. M. LEE,  
S. M. KALLAL & M. FELDMAN
- 577 Megestrol acetate therapy for anorexia and  
weight loss in children with malignant solid  
tumours. C. AZCONA, L. CASTRO, E. CRESPO,  
M. JIMÉNEZ & L. SIERRASESÚMAGA
- 587 Factors affecting dose selection and outcome of  
cisapride treatment for dyspepsia in primary  
care. H. BRUNNER & AUSTRO-CIS STUDY  
GROUP
- 595 Selective 5-hydroxytryptamine antagonism: a  
role in irritable bowel syndrome and functional  
dyspepsia? D. G. MAXTON, J. MORRIS &  
P. J. WHORWELL
- 601 Systemic availability of 5-aminosalicylic acid:  
comparison of delayed release and an azo-bond  
preparation. P. GIONCHETTI, M. CAMPIERI,  
A. VENTURI, F. RIZZELLO, M. FERRETTI,  
C. BRIGNOLA & M. MIGLIOLI
- 607 Antral gastrin cell hyperfunction and  
*Helicobacter pylori* infection. B. ANNIBALE,  
G. RINDI, G. D'AMBRA, M. MARIGNANI,  
E. SOLCIA, C. BORDI & G. DELLE FAVE
- 617 One-week triple therapy with omeprazole,  
amoxycillin and clarithromycin for treatment of  
*Helicobacter pylori* infection. M. M. YOUSFI,  
H. M. T. EL-ZIMAITY, R. M. GENTA &  
D. Y. GRAHAM

Continued overleaf

- 623 The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of *Helicobacter pylori*. J. W. WYETH, R. E. POUNDER, A. E. DUGGAN, C. A. O'MORAIN, H. D. SCHAUFELBERGER, E. H. DE KOSTER, E. A. J. RAUWS, K. D. BARDHAN, J. GILVARRY, M. J. M. BUCKLEY, P. A. GUMMETT & R. P. H. LOGAN
- 631 Enhanced eradication of *Helicobacter pylori* by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic therapy. J. C. ATHERTON, D. J. E. CULLEN, G. E. KIRK, C. J. HAWKEY & R. C. SPILLER
- 637 Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following *Helicobacter pylori* eradication treatment with omeprazole and amoxycillin with or without metronidazole. G. D. BELL, C. M. BATE, A. T. R. AXON, G. TILDESLEY, J. L. MARTIN, M. D. TAYLOR & P. D. I. RICHARDSON
- 645 Long-term follow-up after cure of *Helicobacter pylori* infection with 4 days of quadruple therapy. J. Y. L. LAI, W. A. DE BOER, W. M. M. DRIESSEN & L. M. GEUSKENS
- 651 Bile acid therapy versus placebo before and after extracorporeal shock wave lithotripsy of gallbladder stones. THE EAST-DANISH GALLSTONE STUDY GROUP
- 659 Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome. M. T. TEBANO, G. TRAVERSA, R. DA CAS & A. LOIZZO
- 665 Essential fatty acid supplementation in chronic hepatitis B. A. P. JENKINS, A. T. GREEN & R. P. H. THOMPSON
- 669 Letters to the Editors. M. GUSLANDI AND A. GODDARD & R. SPILLER AND D. E. LANGDON



## VOLUME 10 ISSUE 5 OCTOBER

- 671 Review article: the management of the patient with non-responsive coeliac disease.  
S. O'MAHONY, P. D. HOWDLE & M. S. LOSOWSKY
- 681 Review article: pathogenesis and treatment of chronic hepatic encephalopathy. R. JALAN, J. P. SEERY & S. D. TAYLOR-ROBINSON
- 699 Clinical economics review: the management of gallstone disease. S. H. HUSSAINI
- 707 Clinical economics review: the health-care economic implications of minimal access gastrointestinal surgery. P. J. GUILLOU, A. J. WINDSOR & A. NEJIM
- 715 The effect of a nonabsorbable fat substitute, sucrose polyester, on gastrointestinal function. S. M. KELLY & J. O. HUNTER
- 721 Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. V. CANVA-DELCAMBRE, S. JACQUOT, E. ROBINET, M. LÉMANN, C. DROUET, M. LABALETTE, J.-P. DESSAINT, D. BENGOUFA, C. RABIAN, R. MODIGLIANI, J. WIJDENES, J.-P. REVILLARD & J.-F. COLOMBEL
- 729 Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. A. H. STEINHART, T. HIRUKI, A. BRZEZINSKI & J. P. BAKER
- 737 Xanthine oxidase activity is not increased in the colonic mucosa of ulcerative colitis. P. D. REYNOLDS, S. T. RHENIUS & J. O. HUNTER
- 743 Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man. C. E. GRIMLEY, J. M. WEST, D. E. LOFT, J. COTTRELL, S. G. MANN, L. STAUFFER & C. U. NWOKOLO
- 749 Low-dose famotidine and ranitidine as single post-prandial doses: a three-period placebo-controlled comparative trial. T. G. REILLY, S. SINGH, J. COTTRELL, S. G. MANN, L. STAUFFER & R. P. WALT
- 757 Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. A. S. MEE, J. L. ROWLEY & THE LANSOPRAZOLE CLINICAL RESEARCH GROUP
- 765 Influence of loperamide on lactose handling and oral-caecal transit time. A. SZILAGYI, R. SALOMON & E. SEIDMAN
- 771 *In vitro* dissolution profiles of enteric coated microsphere/microtablet pancreatin preparations at different pH values. K.-H. GAN, W. P. GEUS, W. BAKKER, C. B. H. W. LAMERS & H. G. M. HEIJERMAN
- 777 A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. C. N. BERNSTEIN, L. L. SEEGER, P. A. ANTON, L. ARTINIAN, S. GEFFREY, W. GOODMAN, T. R. BELIN & F. SHANAHAN
- 787 Mebeverine alters small bowel motility in irritable bowel syndrome. P. R. EVANS, Y.-T. BAK & J. E. KELLOW
- 795 Differing actions of the acute administration of propranolol and isosorbide-5-mononitrate on the portal circulation. E. H. FORREST, R. JALAN, D. N. REDHEAD & P. C. HAYES
- 801 Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis. E. H. FORREST, A. J. STANLEY, D. N. REDHEAD, A. J. MCGILCHRIST & P. C. HAYES
- 807 Subcutaneously-administered recombinant human  $\beta$ -interferon in the treatment of chronic hepatitis B virus infection. R. GUAN, K. G. YEOH, I. YAP, J. Y. KANG, A. WEE & R. SMITH
- 815 The palatability of five colonic lavage solutions. F. H. DIAB & J. B. MARSHALL

Continued overleaf

- 821 Effects of lansoprazole plus amoxycillin on curing *Helicobacter pylori* infection in Japanese peptic ulcer patients. M. KATO, M. ASAKA, M. KUDO, M. SUKEGAWA, M. KATAGIRI, T. KOSHIYAMA, H. KAGAYA, K. NISHIKAWA, K. HOKARI, H. TAKEDA & T. SUGIYAMA
- 829 Omeprazole versus ranitidine: short-term triple-therapy in patients with *Helicobacter pylori*-positive duodenal ulcer. A. SPADACCINI, C. DE FANIS, G. SCIAMPA, V. MASCIULLI, U. PANTALEONE, M. DI VIRGILIO, C. MAGNARINI & G. PIZZICANNELLA
- 833 Corrigendum. G. DORTA



## VOLUME 10 ISSUE 6 DECEMBER

- 835 Review article: antibiotic-induced *Clostridium difficile* infection. C. D. SETTLE & M. H. WILCOX
- 843 Review article: symptom improvement through eradication of *Helicobacter pylori* in patients with non-ulcer dyspepsia. R. J. F. LAHEIJ, J. B. M. J. JANSEN, E. H. VAN DE LISDONK, J. L. SEVERENS & A. L. M. VERBEEK
- 851 Review article: methotrexate in gastroenterology—dangerous villain or simply misunderstood? H. TANG & J. NEUBERGER
- 859 Review article:  $\beta_3$ -adrenoceptor agonists—future anti-inflammatory drugs for the gastrointestinal tract? A. ANTHONY
- 865 Clinical economics review: cost-effectiveness of treatment alternatives for gastro-oesophageal reflux disease. S. SRIDHAR, J. HUANG, B. J. O'BRIEN & R. HUNT
- 875 The effects of cisapride on the topography of oesophageal peristalsis. A. STAIANO & R. E. CLOUSE
- 883 Sublingual nitroglycerine: effects on contractile activity of the distal oesophagus and lower oesophageal sphincter in healthy men. G. STACHER, C. SCHNEIDER, H. STEININGER, U. SATZINGER & U. WEBER
- 889 Prescribing patterns for dyspepsia in primary care: a prospective study of selected general practitioners. K. BODGER, M. J. DALY & R. V. HEATLEY
- 897 Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. N. J. V. BELL & R. H. HUNT
- 905 Effects of ranitidine bismuth citrate on gastric acid secretion and gastrin release in subjects with and without *Helicobacter pylori* infection. A. A. CIOCIOLA, D. D. WEBB, A. HEATH & J. H. WALSH
- 913 Effervescent and standard formulations of ranitidine—a comparison of their pharmacokinetics and pharmacology. R. G. P. WATSON, B. T. JOHNSTON, T. C. K. THAM & K. KERSEY
- 919 Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. B. COFFIN, D. BOUHASSIRA, R. CHOLLET, B. FRAITAG, C. DE MEYNARD, J. GENEVE, M. LEMANN, J.-C. WILLER & R. JIAN
- 927 Effects of rebamipide on bile acid-induced inhibition of gastric epithelial repair in a rabbit cell culture model. S. WATANABE, X.-E. WANG, M. HIROSE, T. YOSHIZAWA, R. IWAZAKI, H. OIDE, T. KITAMURA, H. MIWA, A. MIYAZAKI & N. SOTO
- 933 Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506. Y. HISANAGA, H. GOTO, K. TACHI, T. HAYAKAWA & S. SUGIYAMA
- 941 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. G. L. STRETCH, B. J. CAMPBELL, A. D. DWARAKANATH, M. YAQOOB, A. STEVENSON, A. I. MORRIS & J. M. RHODES
- 949 Adverse events in patients treated with 5-aminosalicylic acid: 1993–1994 pharmacovigilance report for Pentasa in France. P. MARTEAU, F. NELET, M. LE LU & C. DEVAUX
- 957 Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis—a randomized single blind comparative study. S. ARDIZZONE, M. PETRILLO, M.-A. ANTONACCI & G. BIANCHI PORRO
- 961 A prospective randomized trial of colchicine in prevention of liver cirrhosis in chronic hepatitis B patients. D.-Y. LIN, I.-S. SHEEN, C.-M. CHU & Y.-F. LIAW
- 967 Could oral erythromycin optimize high energy continuous enteral nutrition? C. LANDRY, N. VIDON, P. SOGNI, P. NEPVEUX, J.-C. CHAUMEIL, D. COUTURIER & S. CHAUSSADE

Continued overleaf

- 975 A double-blind randomized trial of low-dose versus high-dose topical anaesthesia in unsedated upper gastrointestinal endoscopy. H. E. MULCAHY, R. R. S. H. GREAVES, A. BALLINGER, S. E. PATCHETT, A. RICHES, P. D. FAIRCLOUGH & M. J. G. FARTHING
- 981 Intravenous midazolam as a sedative for colonoscopy: a randomized, double-blind clinical trial. K. YUNO, H. IISHI, M. TATSUTA, K. HIFUMI & M. OMORI
- 985 Feasibility of analyzing [ $^{13}\text{C}$ ]urea breath tests for *Helicobacter pylori* by gas chromatography-mass spectrometry in the selected ion monitoring mode. V. N. KASHO, S. CHENG, D. M. JENSEN, H. AJIE, W.-N. P. LEE & L. D. FALLER
- 997 *Helicobacter pylori* eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. G. CAMMAROTA, A. TURSI, A. PAPA, M. MONTALTO, G. VENETO, L. CUOCO, G. FEDELI & G. GASBARRINI
- 1001 High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of *Helicobacter pylori* infection. H. MALATY, H. M. T. EL-ZIMAITY, R. M. GENTA, R. A. COLE & D. Y. GRAHAM
- 1005 Lansoprazole, clarithromycin and metronidazole for seven days in *Helicobacter pylori* infection. A. W. HARRIS, D. I. PRYCE, S. M. GABE, Q. N. KARIM, M. M. WALKER, H. LANGWORTHY, J. H. BARON & J. J. MISIEWICZ
- 1009 *Helicobacter pylori* eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. A. F. GODDARD & R. C. SPILLER
- 1015 One week triple therapy with omeprazole, clarithromycin and tinidazole for *Helicobacter pylori*: differing efficacy in previously treated and untreated patients. M. MOSHKOWITZ, F. M. KONIKOFF, Y. PELED, S. BRILL, A. HALLAK, E. TIOMNY, M. SANTO, Y. BUJANOVER & T. GILAT
- 1021 Cure of *Helicobacter pylori* infection in the elderly: effects of eradication on gastritis and serological markers. A. PILOTTO, F. DI MARIO, M. FRANCESCHI, G. LEANDRO, G. SOFFIATI, M. SCAGNELLI, L. BOZZOLA & G. VALERIO
- 1029 Randomized comparison of differing durations of twice-a-day triple therapy for the eradication of *Helicobacter pylori*. L. LAINE, R. ESTRADA, M. TRUJILLO, K. FUKANAGA & G. NEIL
- 1035 Letters to the Editors. A. HARRIS & J. J. MISIEWICZ AND W. L. PETERSON AND R. J. PLAYFORD & C. E. MACDONALD AND J. S. DIXON & J. R. WOOD
- 1037 Index

